Entyvio (Vedolizumab) Patient Guide for IBD: Common Questions
Content note: Educational content aligned with publicly available patient materials from the Crohn's & Colitis Foundation and other major IBD education sources. IBDPal is not affiliated with or endorsed by the Foundation. Last reviewed June 2026. Not individual medical advice.
Educational use only. IBDPal does not provide medical advice, diagnosis, or treatment. Always consult your gastroenterologist or IBD care team for personal decisions.
Entyvio is the brand name for vedolizumab, a gut-selective biologic used for ulcerative colitis and Crohn's disease in appropriate patients. This FAQ explains common patient questions in plain language. It is educational only and does not recommend starting, stopping, or dosing any medicine. Decisions belong to you and your gastroenterologist.
What patients usually understand about how it works
Vedolizumab targets immune cell trafficking toward the gut more selectively than some systemic biologics. That gut focus is why many people ask about infection risk and vaccine timing. Your clinician will still screen for infections and review your full history before and during therapy. For class context, see understanding biologics in IBD.
How treatment is commonly given
Vedolizumab is typically given as an intravenous infusion on an induction schedule, then maintenance infusions at intervals your specialist sets. Some patients later discuss subcutaneous options where available and approved for their situation. Infusion centers vary in length of visit and premedication practices. Practical day-of tips live in infusion day what to expect.
Questions to ask before your first infusion
- What screening labs or tuberculosis tests do I need first?
- How will we judge response at 6 to 14 weeks?
- What infections or symptoms should I report the same day?
- How does this medicine interact with my vaccines and travel plans?
- What is the plan if insurance delays the next dose?
What many patients monitor between visits
Track stool frequency, blood, urgency, energy, and any new infections. Attend lab draws your team orders. Keep immunization records current and review vaccines with biologics and immunosuppressants. Report fever, severe headache, rash, jaundice, or progressive abdominal pain promptly.
Insurance and access logistics
Specialty pharmacy and medical-benefit infusions follow different paperwork paths. Use the prior authorization timeline and insurance biologics overview to stay organized. Manufacturer support programs exist for some patients; eligibility varies.
What this guide does not do
It does not compare brands for you, predict your remission odds, or replace the prescribing information your clinician and pharmacist use. Side effect lists and contraindications are individual. If you are pregnant, planning pregnancy, or breastfeeding, ask for tailored counseling.
CCF and clinical society materials encourage informed shared decisions about biologics, including vedolizumab, with clear follow-up plans rather than one-time prescriptions. Bring a written list of goals for the first three months so visits stay focused on response, safety, and quality of life instead of only scheduling the next infusion.
Related: first 12 weeks on a biologic, understanding biologics, infusion day.
Read the full interactive version on ibdpal.org.